How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

6,033 results for

Iron Deficiency Anemia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Iron (III) Isomaltoside 1000 (Monoferric) - iron deficiency anemia

Iron (III) Isomaltoside 1000 (Monoferric) - iron deficiency anemia Iron (III) Isomaltoside 1000 | CADTH.ca Find the information you need Iron (III) Isomaltoside 1000 Iron (III) Isomaltoside 1000 Last Updated: October 3, 2019 Result type: Reports Project Number: SR0622-000 Product Line: Generic Name: Iron (III) Isomaltoside 1000 Brand Name: Monoferric Manufacturer: Pharmacosmos A/S Indications: iron deficiency anemia Manufacturer Requested Reimbursement Criteria 1 : Reimbursed for the treatment (...) of iron deficiency anemia in adult patients who have intolerance or unresponsiveness to oral iron therapy. The diagnosis must be based on laboratory tests. Submission Type: New Project Status: Active Biosimilar: No Companion Diagnostics: No Fee Schedule: Schedule A The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable. Key Milestones 2 Call

2019 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

2. Ferric maltol (Accrufer) - To treat iron deficiency anemia in adults

Ferric maltol (Accrufer) - To treat iron deficiency anemia in adults Drug Approval Package: ACCRUFER U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ACCRUFER Company: Shield Therapeutics (UK) Ltd. Application Number: 212320 Approval Date: 07/25/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF

2019 FDA - Drug Approval Package

3. Iron deficiency anaemia in adults

Iron deficiency anaemia in adults Iron deficiency and anaemia in adults RCN guidance for nursing staff This publication is supported by industry. Full information inside.This publication is due for review in June 2018. To provide feedback on its contents or on your experience of using the publication, please email publications.feedback@rcn.org.uk RCN Legal Disclaimer This publication contains information, advice and guidance to help members of the RCN. It is intended for use within the UK (...) and Transplant Sheila Johnston RGN, BSc, MSc, Lead Nurse, Chronic Kidney Disease, Royal Free London NHS Foundation Trust Isobel Mason RGN, MSc, MCGI, Nurse Consultant, Gastroenterology, Royal Free London NHS Foundation Trust Emma Whitmore RGN, Patient Blood Management Practitioner, NHS Blood and Transplant This guidance contains scientific material produced by the RCN with financial support from Vifor Pharma UK Ltd. Vifor Pharma have provided some iron deficiency anaemia information and advice on the IV iron

2019 Royal College of Nursing

4. Iron deficiency anaemia

Iron deficiency anaemia Iron deficiency anaemia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Iron deficiency anaemia Last reviewed: February 2019 Last updated: March 2018 Summary Clinical history, presentation, and findings include fatigue, pallor, dyspnoea on exertion, and pica. Microcytic, hypochromic anaemia; low reticulocyte count. Characteristics include low serum iron, increased total iron-binding capacity (...) (TIBC), less than 16% transferrin saturation, and low serum ferritin. The diagnosis of iron deficiency anaemia necessitates investigation of the underlying cause. Initial treatment includes oral iron. Definition The WHO defines anaemia as haemoglobin <130 g/L (13 g/dL) in men older than age 15 years, <120 g/L (12 g/dL) in non-pregnant women older than age 15 years, and <110 g/L (11 g/dL) in pregnant women. Goddard AF, James MW, McIntyre AS, et al. Guidelines for the management of iron deficiency

2018 BMJ Best Practice

5. Iron Deficiency and Anaemia in Adults

impact on preventing anaemia. Maintaining adequate oxygen levels in patients who become anaemic can help the body to recover and tolerate the anaemia. Diagnosis and treatment of anaemia The measurement of both haemoglobin and ferritin levels prior to surgery can be used to diagnose anaemia and iron deficiency, respectively. The WHO define anaemia as haemoglobin <130 g/l in men and <120 g/l in women, although some guidelines recommend that the <130 g/l cut off should be applied to both men and women (...) Iron Deficiency and Anaemia in Adults CLINICAL PROFESSIONAL RESOURCE Iron Deficiency and Anaemia in Adults RCN guidance for nursing practice This publication is supported by industryIRON DEFICIENCY AND ANAEMIA IN ADULTS: RCN GUIDANCE FOR NURSING PRACTICE 2 Acknowledgements The authors would like to thank the UK-wide groups, organisations and individuals who have contributed to this Royal College of Nursing publication. Authors Carys Barton, RGN, Lead Nurse for Heart Failure, Clinical

2018 Royal College of Nursing

8. Monoferric - treatment of iron deficiency anemia

Monoferric - treatment of iron deficiency anemia Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012

2018 Health Canada - Drug and Health Product Register

9. How do I use CosmoFer (iron dextran) total dose infusion for correction of iron deficiency anaemia?

How do I use CosmoFer (iron dextran) total dose infusion for correction of iron deficiency anaemia? How do I use CosmoFer (iron dextran) total dose infusion for correction of iron deficiency anaemia? – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice Menu · · 27th November 2019 · UKMi This updated Medicines Q&A provides guidance on the administration of Cosmofer (iron dextran) total dose infusion for the treatment of iron deficiency anaemia Attachments · Word

2019 Specialist Pharmacy Services

10. How can we diagnose iron deficiency in the setting of anemia of chronic disease?

How can we diagnose iron deficiency in the setting of anemia of chronic disease? Chiefs’ Inquiry Corner – 11/11/19 – Clinical Correlations Search Chiefs’ Inquiry Corner – 11/11/19 November 11, 2019 2 min read Many patients with anemia of chronic disease will also be iron deficient. However, diagnosing underlying iron deficiency is challenging in the setting of inflammation because cytokines and inflammatory mediators reduce duodenal iron absorption and sequester iron in macrophages and ferritin (...) . Thus ferritin does not accurately reflect iron stores in patients with chronic disease. A newer blood test called a “soluble transferrin receptor” (sTfR) is an indirect measure of erythropoiesis that is less affected by an inflammatory state. There is growing evidence that this test, alone or divided by log ferritin values (ferritin index) can help detect underlying iron deficiency in patients with anemia of chronic disease. References: It is critical to determine if patients with NAFLD have

2019 Clinical Correlations

11. Ferric carboxymaltose for iron deficiency anaemia

Ferric carboxymaltose for iron deficiency anaemia '); } else { document.write(' '); } ACE | Ferric carboxymaltose for treating iron deficiency anaemia Search > > Ferric carboxymaltose for treating iron deficiency anaemia - Ferric carboxymaltose for treating iron deficiency anaemia Published on 2 September 2019 Guidance Recommendations The Ministry of Health's Drug Advisory Committee has recommended: Ferric carboxymaltose 500 mg/10 mL solution for injection/infusion for treating iron deficiency (...) anaemia when oral iron preparations are ineffective or cannot be used. Subsidy status Ferric carboxymaltose 500 mg/10 mL solution for injection/infusion is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication. SDL subsidy does not apply to ferric carboxymaltose 100 mg/2 mL injection. Quicklinks | | | | | Copyrights © 2019 Ministry of Health, Singapore. Last Updated on 2 September 2019

2019 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

12. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. (Abstract)

Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. Intravenous iron enables rapid correction of iron-deficiency anemia, but certain formulations induce fibroblast growth factor 23-mediated hypophosphatemia.To compare risks of hypophosphatemia and effects on biomarkers of mineral and bone homeostasis of intravenous iron isomaltoside (now known as ferric derisomaltose) vs ferric carboxymaltose.Between October 2017 (...) and June 2018, 245 patients aged 18 years and older with iron-deficiency anemia (hemoglobin level ≤11 g/dL; serum ferritin level ≤100 ng/mL) and intolerance or unresponsiveness to 1 month or more of oral iron were recruited from 30 outpatient clinic sites in the United States into 2 identically designed, open-label, randomized clinical trials. Patients with reduced kidney function were excluded. Serum phosphate and 12 additional biomarkers of mineral and bone homeostasis were measured on days 0, 1, 7

2020 JAMA

13. Management of Anaemia and Iron Deficiency in Patients With Cancer: ESMO Clinical Practice Guidelines

Management of Anaemia and Iron Deficiency in Patients With Cancer: ESMO Clinical Practice Guidelines CLINICAL PRACTICE GUIDELINES Managementof anaemiaandirondeficiencyin patients with cancer: ESMO Clinical Practice Guidelines † M. Aapro 1 , Y. Beguin 2,3 , C. Bokemeyer 4 , M. Dicato 5 , P. Gasco ´n 6 , J. Glaspy 7 , A. Hofmann 8 , H. Link 9 , T. Littlewood 10 , H. Ludwig 11 ,A.O ¨ sterborg 12 , P. Pronzato 13 , V. Santini 14 , D. Schrijvers 15 , R. Stauder 16 , K. Jordan 17 & J. Herrstedt 18,19 (...) of interest. References 1. Ludwig H, Van Belle S, Barrett-Lee P. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey de?ning the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293–2306. 2. Ludwig H, Muldur E, Endler G, Hubl W. Prevalence of iron de?ciency across different tumors and its association with poor performance sta- tus, disease status and anemia. Ann Oncol 2013; 24: 1886–1892. 3. Delarue R, Tilly H, Salles GA et al

2018 European Society for Medical Oncology

14. Routine iron supplementation and screening for iron deficiency anemia in pregnant women

Routine iron supplementation and screening for iron deficiency anemia in pregnant women Routine iron supplementation and screening for iron deficiency anemia in pregnant women Routine iron supplementation and screening for iron deficiency anemia in pregnant women McDonagh M, Cantor A, Bougatsos C, Dana T, Blazina I Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation McDonagh M, Cantor A, Bougatsos C, Dana T, Blazina I. Routine iron supplementation and screening for iron deficiency anemia in pregnant women. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Synthesis No. 123. 2015 Authors' objectives To systematically update the prior USPSTF reviews on screening and supplementation for iron deficiency anemia in pregnancy. Authors' conclusions Evidence supports the effectiveness of routine iron supplementation during

2015 Health Technology Assessment (HTA) Database.

15. Routine iron supplementation and screening for iron deficiency anemia in children ages 6 to 24 months: a systematic review to update the U.S. Preventive Services Task Force Recommendation

Routine iron supplementation and screening for iron deficiency anemia in children ages 6 to 24 months: a systematic review to update the U.S. Preventive Services Task Force Recommendation Routine iron supplementation and screening for iron deficiency anemia in children ages 6 to 24 months: a systematic review to update the U.S. Preventive Services Task Force Recommendation Routine iron supplementation and screening for iron deficiency anemia in children ages 6 to 24 months: a systematic review (...) to update the U.S. Preventive Services Task Force Recommendation McDonagh M, Blazina I, Dana T, Cantor A, Bougatsos C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McDonagh M, Blazina I, Dana T, Cantor A, Bougatsos C. Routine iron supplementation and screening for iron deficiency anemia in children ages 6 to 24 months: a systematic review

2015 Health Technology Assessment (HTA) Database.

16. Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial. (Abstract)

Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial. Anaemia and iron deficiency are frequent in patients scheduled for cardiac surgery. This study assessed whether immediate preoperative treatment could result in reduced perioperative red blood cell (RBC) transfusions and improved outcome.In this single-centre, randomised, double-blind, parallel-group controlled study, patients undergoing elective cardiac (...) surgery with anaemia (n=253; haemoglobin concentration (Hb) <120 g/L in women and Hb <130 g/L in men) or isolated iron deficiency (n=252; ferritin <100 mcg/L, no anaemia) were enrolled. Participants were randomly assigned (1:1) with the use of a computer-generated range minimisation (allocation probability 0·8) to receive either placebo or combination treatment consisting of a slow infusion of 20 mg/kg ferric carboxymaltose, 40 000 U subcutaneous erythropoietin alpha, 1 mg subcutaneous vitamin B12

2019 Lancet Controlled trial quality: predicted high

17. A prospective, multicenter, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia (the FERWON-IDA trial). Full Text available with Trip Pro

A prospective, multicenter, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia (the FERWON-IDA trial). Iron deficiency anemia (IDA) is prevalent, and intravenous iron, especially if given in a single dose, may result in better adherence compared with oral iron. The present trial (FERWON-IDA) is part of the FERWON program with iron isomaltoside 1000/ferric derisomaltose (IIM), evaluating safety and efficacy of high dose IIM in IDA patients (...) of mixed etiologies. This was a randomized, open-label, comparative, multi-center trial conducted in the USA. The IDA patients were randomized 2:1 to a single dose of 1000 mg IIM, or iron sucrose (IS) administered as 200 mg intravenous injections, up to five times. The co-primary endpoints were adjudicated serious or severe hypersensitivity reactions, and change in hemoglobin from baseline to week eight. A total of 1512 patients were enrolled. The frequency of patients with serious or severe

2019 American journal of hematology Controlled trial quality: uncertain

18. Iron isomaltoside is superior to iron sucrose in increasing hemoglobin in gynecological patients with iron deficiency anemia. Full Text available with Trip Pro

Iron isomaltoside is superior to iron sucrose in increasing hemoglobin in gynecological patients with iron deficiency anemia. 29569727 2019 05 15 2019 08 02 1096-8652 93 6 2018 06 American journal of hematology Am. J. Hematol. Iron isomaltoside is superior to iron sucrose in increasing hemoglobin in gynecological patients with iron deficiency anemia. E148-E150 10.1002/ajh.25094 Derman Richard R Thomas Jefferson University, Philadelphia, Pennsylvania. Roman Eloy E Lakes Research, Miami Lakes (...) . Gov't United States Am J Hematol 7610369 0361-8609 0 Disaccharides 0 Ferric Compounds 0 Hemoglobins 3M6325NY1R iron isomaltoside 1000 FZ7NYF5N8L Ferric Oxide, Saccharated IM Adult Anemia, Iron-Deficiency drug therapy Disaccharides administration & dosage Female Ferric Compounds administration & dosage Ferric Oxide, Saccharated administration & dosage Hemoglobins analysis drug effects Humans Menorrhagia Pregnancy Quality of Life Treatment Outcome Young Adult 2018 03 15 2018 03 19 2018 3 24 6 0 2019 5

2019 American journal of hematology Controlled trial quality: uncertain

19. Iron Bisglycinate Chelate and Polymaltose Iron for the Treatment of Iron Deficiency Anemia: A Pilot Randomized Trial. Full Text available with Trip Pro

Iron Bisglycinate Chelate and Polymaltose Iron for the Treatment of Iron Deficiency Anemia: A Pilot Randomized Trial. Iron Deficiency Anemia (IDA) is a major public health problem worldwide. Iron Bisglycinate Chelate (FeBC) and polymaltose iron (FeP) are used for the treatment of IDA and exhibit good tolerability with a low incidence of adverse effects. However, these compounds have important differences in their structures and bioavailability.To compare the efficacy of oral supplementation (...) with FeBC and FeP in anemic children.In this double-blind study, children aged 1 to 13 years who were diagnosed with IDA were randomly divided into two groups: i) FeBC, supplemented with iron bisglycinate chelate, and ii) FeP, supplemented with polymaltose iron (3.0 mg iron/kg body weight/day for 45 days for both groups).Both treatments resulted in significant increases in hemoglobin levels, Mean Corpuscular Volume (MCV) and Cell Distribution Width (RDW) and in a reduction of transferrin levels

2019 Current pediatric reviews Controlled trial quality: uncertain

20. Total dose iron dextran infusion versus oral iron for treating iron deficiency anemia in pregnant women: a randomized controlled trial. (Abstract)

Total dose iron dextran infusion versus oral iron for treating iron deficiency anemia in pregnant women: a randomized controlled trial. To test safety, efficacy, and cost-effectiveness of total dose infusion (TDI) of low molecular weight (LMW) iron dextran for treatment of iron deficiency anemia (IDA) during pregnancy in comparison to oral ferrous fumarate.Prospective interventional randomized controlled trial (RCT). Design classification. Canadian Task Force II3.Antenatal clinic and causality (...) unit of a tertiary care referral facility and University Hospital.A total 66 anemic pregnant women (hemoglobin level between 7-10 g/dl).Administration of a LMW iron dextran as a TDI (group A) or Oral iron ferrous fumarate 60 mg elemental iron three times daily (group B) followed by remeasurement of hemoglobin after 4 weeks.The main outcome measure was clinical and laboratory improvement of anemia after 4 weeks of starting the therapy. Both groups showed a significant clinical improvement of anemia

2019 The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>